COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020 – Volume 26, Number 10—October 2020 – Emerging Infectious Diseases journal – CDC

A 40-year-old man was admitted to Pontchaillou University Hospital, Rennes, France, for treatment of COVID-19. His medical history was remarkable only for pulmonary sarcoidosis, diagnosed in 2015; it was well controlled with hydroxychloroquine (200 mg 2×/d) with no other immunomodulatory drugs and no adherence issues. Twelve days before admission, he had received a diagnosis of COVID-19 in the outpatient department after a 4-day course of cough, myalgia, and low-grade fever. He had positive results by PCR for SARS-CoV-2 on a nasopharyngeal sample (RdRp gene; Pasteur COV_IP2/4, Paris, France;

Source: COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020 – Volume 26, Number 10—October 2020 – Emerging Infectious Diseases journal – CDC